The present work was a randomized comparative study of two injectable progestogen-only contraceptives. The first group (200 subjects) received 150 mg of depotmedroxyprogesterone acetate (Depoprovera) every 84 +/- 7 days and the second (200 subjects) received 200 mg of norethisterone enanthate (Noristerat) every 56 +/- 7 days. Acceptors of injectable contraceptives in Assiut, Egypt, were mainly women looking for fertility termination. Menstrual disruption was the main side effect among both treatment groups. Amenorrhoea was the commonest menstrual complaint and was the main reason for discontinuation in both groups. Only one pregnancy occurred during NET-EN use; two more pregnancies occurred, one in each of the two groups but there were indications that conception preceded the first injection. Menstrual irregularities were generally more frequent with DMPA users. However, DMPA had better one-year continuation rates than NET-EN (68.8 +/- 3.5 and 57.1 +/- 3.6 per 100 women, respectively).

Adolescent↗

PubMed1988

Safe motherhood.

Explore the source record for details and available documents.

Developing Countries↗

PubMed1988

Promotion of research in human reproduction: global needs and perspectives.

The WHO Special Programme of Research, Development and Research Training in Human Reproduction was established in 1972, to respond to a global expansion in research needs in human reproduction, especially in the area of fertility regulation. The Programme's limited resources come from voluntary contributions by governments and international agencies. The emphasis is always on the needs of developing countries. The Programme has to keep the field under continuous review, and to direct its limited resources to the major unmet needs. This paper presents, from a global perspective, the needs and priorities in the promotion of research in human reproduction. It is emphasized that research has to be backed up by political commitment and resources if it is to have an impact on reproductive health. The role of determinants of health, other than and beyond the medical services, has also to be recognized. Promotion of research in human reproduction, to serve developing country needs, has to move into two directions. One is the mobilization of a global effort to develop and test technologies, where the available technologies are not satisfactory to meet the needs and where the research is slackening. The second is the strengthening of in-country resources for research to deal with country-specific problems and to enable countries to utilize, to the best, available technologies.

Contraception↗

PubMed1988

Family planning linked to an obstetric service.

Explore the source record for details and available documents.

Breast Feeding↗

PubMed1977

Surgical sterilization.

Explore the source record for details and available documents.

Female↗

PubMedDate not supplied

Reproductive health: a global overview.

A global overview of reproductive health outlines major challenges for action. Worldwide, 60 million to 80 million couples suffer from infertility. At the same time, there is a striking unmet need for contraception in developing countries. Unsafe abortion practices result in between 115,000 and 204,000 deaths each year. Female genital mutilation in one form or another continues to exist in around 40 countries. A second generation of organisms has now made sexually transmitted diseases the most common group of notifiable diseases in most countries. For the year 2000, it is projected that there will be a cumulative total of about 40 million HIV infections in men, women and children. About half a million women die each year because of complications related to pregnancy and childbirth. A total of about 15 million infants and children die annually, mostly from preventable childhood diseases. At least 17% of all babies in developing countries are born with a low birth weight.

Acquired Immunodeficiency Syndrome↗